October 24, 2018
“Yearly CT scans of high-risk lung cancer patients has increased the early diagnosis of lung cancer as well as the identification of pulmonary nodules. Yet not all lung nodules are cancerous. The BDX-XL2 test has shown early promise in ruling out cancer through blood samples, including a finding by the pulmonary nodule plasma proteomic classifier ... Read more
August 31, 2018
“The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).”
Read the full story.
August 22, 2018
“…the growing use of ddPCR assays for identifying the subset of patients who should be placed on targeted therapy options is providing carefully measured results with rapid turnaround time for optimal clinical utility. This approach enabled by liquid biopsy means that physicians do not have to wait weeks for genomic information that may enable the ... Read more
August 3, 2018
“Methods for measuring ctDNA, circulating tumour RNA (ctRNA), and circulating proteomic signatures from the blood are non-invasive and provide diagnostic and independent prognostic information that can help drive therapeutic strategy, as well as facilitate patient-physician conversations about prognosis and care preferences.” Read the full story.
June 19, 2018
“In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians who are evaluating an NSCLC patient’s eligibility for anti-PD-L1 therapy.” Read the full story.
April 19, 2018
“These promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test as well as the possibility of identifying a meaningful, clinically relevant threshold for the assay. Consequently, Biodesix has combined with collaborators in its physician network, including FirstHealth Moore Regional Hospital and Pinehurst Medical Clinic, to validate the assay by analyzing prospectively ... Read more
March 23, 2018
“In our experience, we have found it beneficial to collect the liquid biopsy at the time of the initial tissue diagnosis if NSCLC is suspected by bedside pathology with rapid onsite evaluation (ROSE). The blood is stored by the company that operates the assay at no cost to the patient or the institution. Once a ... Read more
March 20, 2018
“I see ddPCR as the future of personalized cancer therapies. Based on our cancer center’s successful experience with the technology, I believe it is only a matter of time before these kinds of blood-based liquid biopsies become an indispensable method for doctors to categorize a patient’s disease and determine the best course of treatment.” – ... Read more
February 5, 2018 “Liquid biopsies are becoming more and more accepted, particularly by community physicians seeking timely diagnostic test results to inform treatment decisions. The number of treatment options, especially in certain disease states, like lung cancer, are multiplying rapidly, and the demand for testing that can help physicians determine which patients are most likely to benefit from ... Read more
December 21, 2017 From Clinical Lab Products: “Measurement of PD-L1 is challenging not only when tissue is lacking, but due to the inherent complexity of immunohistochemistry,” says Pritchett. “The testing approach demonstrated in this study shows promise as a method of assessing PD-L1 in plasma. A more objective measure of PD-L1 status could offer a path to better ... Read more